{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ00169",
      "entity_text" : "hIL6R",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ00180",
      "entity_text" : "tocilizumab",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Treatment with tocilizumab markedly prevented the development of splenomegaly in male Il6ra hIL6R / hIL6R -hIL6 transgenic mice (XREF_FIG; XREF_SUPPLEMENTARY) : the spleen weights at the end of 4-week treatment were decreased to 0.14 +/- 0.03 g, 0.14 +/- 0.02 g and 0.13 +/- 0.03 g in groups treated with 0.1, 0.25 and 0.5 mg/body of tocilizumab, respectively.",
  "reading_complete" : "2020-08-04T09:02:52Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T09:01:17Z",
  "trigger" : "prevented",
  "evidence" : [ "tocilizumab markedly prevented the development of splenomegaly in male Il6ra hIL6R" ],
  "pmc_id" : "3561642",
  "score" : 0
}